News Sanofi pledges a $20 billion investment programme in the US Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US.
R&D For cell therapies, raw material quality hinges on the human... When it comes to cell-based therapy manufacturing, the concept of quality management carries important distinctions from more traditional therapeutics production.
News Gilead ups its US investment plans by $11 billion Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.
News FDA ramps up unannounced inspections of foreign facilities Trump orders the FDA to ease the commissioning of domestic manufacturing facilities, as the regulator announces more unannounced foreign inspections.
News GSK "well positioned" to weather pharma tariffs GSK has said it is not too worried about the impact of potential pharma-specific US tariff rules as it posts a solid set of first-quarter results.
News AZ backs up threat of manufacturing shift from Europe AstraZeneca has said it is considering a shift in the production of some medicines from Europe to the US in order to sidestep potential tariffs.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
